Sells Tyvaso inhaled medicines for people with pulmonary hypertension, along with other medicines for pulmonary hypertension and high-risk neuroblastoma; develops technologies to expand transplantable organs.
10-K for FY2025, filed Feb 25, 2026Tyvaso DPI® (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso® (treprostinil) Inhalation Solution (Nebulized Tyvaso), which includes…View ↗
Tyvaso DPI and Nebulized Tyvaso are also approved by the U.S. Food and Drug Administration (FDA) to treat pulmonary hypertension associated…View ↗
In the United States, we also market and sell an oncology product, Unituxin® (dinutuximab) Injection (Unituxin), which is approved by the…View ↗
We sell Tyvaso DPI and Nebulized Tyvaso to specialty pharmaceutical distributors in the United States. We recognized $1,878.2 million…View ↗
In addition, we are developing a new product to treat PAH, ralinepag. We are also heavily engaged in research and development of organ…View ↗
Tyvaso is the largest business: specialty pharmaceutical distributors buy its inhaled medicines, and United Therapeutics is paid after shipment or delivery; distributor balances are generally due within 30 to 90 days.
10-K for FY2025, filed Feb 25, 2026We sell Tyvaso DPI and Nebulized Tyvaso to specialty pharmaceutical distributors in the United States. We recognized $1,878.2 million…View ↗
Revenues are generated from the sale of our commercially approved products: Tyvaso DPI, Nebulized Tyvaso, Remodulin, Orenitram, Unituxin…View ↗
We invoice and receive payment from our customers after we recognize revenue, resulting in receivables from our customers that are…View ↗
10-K for FY2025, filed Feb 25, 2026
FY2025 revenue by product or service ↗$3.2B
10-K for FY2025, filed Feb 25, 2026
$3.2B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Tyvaso
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
59%
FY2022: 45%
|
Tyvaso, FY2025
$1.9B Sources
|
Sold outright |
|
Remodulin
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
17%
FY2022: 26%
|
Remodulin, FY2025
$526.8M Sources
|
Sold outright |
|
Orenitram
Sold outright
10-K for FY2025, filed Feb 25, 2026 |
16%
FY2022: 17%
|
Orenitram, FY2025
$496.9M Sources
|
Sold outright |
|
Unituxin
Sold outright
|
7.1%
FY2022: 9.5%
|
Unituxin, FY2025
$226.8M Sources
|
Sold outright |
|
Adcirca
Sold outright
|
0.9%
FY2022: 2.1%
|
Adcirca, FY2025
$30M Sources
|
Sold outright |
|
Other
|
0.8%
FY2022: 0.7%
|
Other, FY2025
$24M Sources
|
In the U.S., specialty pharmaceutical distributors handle Tyvaso, Remodulin, the pumps and Orenitram; Cencora distributes Unituxin, while Adcirca moves through Lilly’s pharmaceutical wholesale network. International pharmaceutical distributors handle Nebulized Tyvaso, Remodulin and Unituxin.
10-K for FY2025, filed Feb 25, 2026Our total revenues consist primarily of sales of the commercial products noted above, including the delivery devices (in the case of Tyvaso…View ↗
Yes. It kept 42 cents of every revenue dollar as net income in FY2025 and turned 33 cents into free cash flow.
10-Q for Q3 FY2026, filed Nov 4, 2026
$258.6MView ↗
10-Q for Q3 FY2026, filed Nov 4, 2026
Open tableView ↗
Growing. Revenue grew 89% in 4 years, from $1.7B in FY2021 to $3.2B in FY2025, about 17% a year.
New Remodulin pump
The older report describes development of another next-generation Remodulin delivery system; the latest report says the patient-filled RemunityPRO pump launched.
10-K for FY2022, filed Feb 22, 2023 10-K for FY2025, filed Feb 25, 2026Patients must use external pumps manufactured by third parties to deliver Remodulin. Smiths Medical, Inc. (Smiths Medical, now a subsidiary…View ↗
In January 2025, DEKA obtained FDA clearance of a new version of the Remunity Pump, which is intended to improve the patient experience by…View ↗
Competes with Merck
10-K for FY2025, filed Feb 25, 2026Endothelin Receptor Antagonists. PAH patients have also been shown to have elevated levels of endothelin-1, a naturally occurring peptide…View ↗
Loading...